Capture phrases in quotes for more specific queries (e.g. "rocket ship" or "Fred Lynn")

Platform

Techneins™ – Non-natural polymers as synthetic affinity reagents and novel therapeutics

A rapid discovery platform for non-natural polymers that expands our access to 3-dimensional structural diversity with the synthetic accessibility and optimizability of small molecules.

The problem

The development of potent and selective affinity reagents has traditionally been restricted to naturally occurring types of molecules, such as monoclonal antibodies, peptides from phage-display libraries and nucleic acids / aptamers. However, natural biological molecules have limitations in stability, pharmacokinetic (PK) properties, structural and chemical diversity; and may take several months to years to develop as diagnostic and therapeutic agents.

The solution

SRI Biosciences has developed a molecular discovery platform that enables the synthesis and screening of sequence-defined non-natural polymers, or “Techneins™”, to create potent and selective affinity reagents that can be used as either therapeutics or diagnostic reagents.

How it works

Development of application-specific techneins is enabled by a proprietary chemical library design and screening methodology. Unique custom monomer units have been designed to impart stability, strong binding interactions and three-dimensional folding properties into relatively small (4,000 – 7,000 Da) sequence-defined polymers. Large libraries of these polymers (>107 molecules per library) can be screened using our Fiber optic Array Screening Technology (FAST) at a rate of five million compounds per minute. This rapid and automated screening technology enables the development of non-natural synthetic affinity reagents with potent binding affinities, appropriate selectivity and enhanced stabilities and pharmacokinetic (PK) properties over natural molecules.

Validation

Technein non-natural synthetic affinity reagents have been developed against a number of different types of molecular targets including proteins, peptides and a small molecule. In all cases, techneins were discovered from the initial screening with nano- to picomolar binding affinities. Other specific benefits of techneins include:

  • High stability – have demonstrated prolonged stability and activity in the presence of plasma or following treatment with degradation enzymes (proteinase K) and heat (>90°C for 24 hours).
  • Scalable production methods – can be easily produced on a milligram to gram scale using modified peptide synthesis protocols on an automated system.
  • Optimizable – standardized approaches to optimize affinity, selectivity & stability and PK properties.
  • Customizable functionalization – synthetic molecules that can easily be modified or functionalized using synthetic methods for surface attachment, reporter attachment, fluorophore incorporation or multimerization.

Partner with us

SRI Biosciences partners with commercial companies through research collaborations that lead to option and license agreements for further commercialization. We are looking for commercial partners who (1) are interested in using techneins as affinity reagents for diagnostic applications; (2) would like to co-develop techneins as therapeutic inhibitors of a specific biological target; or (3) are interested in exploring new applications for high-stability, synthetic affinity reagents for capturing or purifying target molecules from complex mixtures. Contact biosciences@sri.com to explore partnership opportunities.

September 2019

How can we help?

Discovery ServicesPreclinical/Early Clinical Development ServicesPartnership/CollaborationsBasic Research

Once you hit send…

We’ll match your inquiry to the person who can best help you. Expect a response within 48 hours.

Our Privacy Policy

close check icon

Message Sent

Success! - Thank you for your interest.

cookiebot
cookiebot

SRI and its partners use cookies to improve your browsing experience. If you continue to use this website without changing your cookie settings, you are consenting to the use of cookies by SRI and its partners. For more information on SRI’s privacy practices, including how to decline the use of cookies, please read our Privacy Policy.

I agree
share dwonload plus email external external project copy play call directions linkedin